A 2-of-4 scorecard pairs cash-backed profits and a 19.6% free-cash-flow margin with declining revenue and earnings. The stock trades at 19x earnings, 8% below its high — but only 23% of 12 analysts rate it Buy, against 60% Hold and 17% Sell. Current price: $25.92.
Changes over time: 2 discontinued (Chantix/Champix and Sutent, both after patents expired by 2022), 2 New & Sustained, 2 Evolved, 2 New Products — a portfolio rotating from off-patent products toward oncology and rare-disease franchises.
Pfizer addresses large markets in oncology, vaccines, immunology and rare disease, funded by a portfolio of established brands. The challenge framed in the filing is replacement: revenue and earnings are declining as COVID-era products fade and key patents — including Eliquis and Ibrance over the coming years — approach expiry, putting the weight on the oncology and rare-disease pipeline to offset the erosion.
Pfizer still converts revenue to cash efficiently — a 19.6% free-cash-flow margin supports a dividend yielding around 6.6% — but an 8.3% return on equity and a declining top line keep restnvest's read mixed rather than strong. Value creation depends on deploying that cash, and recent acquisitions, into a pipeline that can replace maturing blockbusters faster than patents erode them. Two of four Financial Scorecard signals are rated strong.
Y = price target. X = days remaining on call (negative = past expected hit window). Bubble size = Anachart Performance Score. Dashed vertical = the expected-hit boundary.
Chart shows 5 of 12 covering analysts. See all on Anachart →
Pfizer pits a cheap, cash-generative profile against a genuinely skeptical Street. The supportive side is concrete: restnvest scores fundamentals 2-of-4, with cash-backed profits and comfortable coverage, a 19.6% free-cash-flow margin funding a roughly 6.6% dividend yield, and a low 19x P/E. The cautious side is just as concrete: revenue and earnings are declining as COVID-era products fade and patents (Eliquis, Ibrance) approach expiry, return on equity is a modest 8.3%, and valuation scores only 1-of-4 sensible with the stock near its high. The analyst lens is the most bearish here — across 12 firms, 60% Hold, 16.67% Sell and just 23.33% Buy, a 56.43% hit ratio, and the latest rating a Sell from RBC's Trung Huynh at $25. The $28.80 average target implies about 11% upside, but the range is narrow ($25-$36) and the conviction is low. A long-term investor weighs a cheap, high-yield, cash-rich business against a declining top line and a professional consensus that is, unusually, leaning negative. Two data notes: Anachart's headline showed a stray dollar upside figure inconsistent with its own average target, so the 11% upside to the $28.80 average is used; and Anachart exposed native performance scores for Pfizer on a roughly 0-3 scale, but for consistency across this group the performanceScore values use the same hit-ratio-based 0-10 proxy applied to the other tickers.
Dive deeper into the fundamentals
See Pfizer's full 6-stage analysis on restnvest →See the full analyst picture
See all 12 analyst price targets on Anachart →